KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Research & Development (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Research & Development data on record, last reported at $978.4 million in Q2 2025.

  • For Q2 2025, Research & Development rose 1.22% year-over-year to $978.4 million; the TTM value through Jun 2025 reached $3.8 billion, up 13.05%, while the annual FY2025 figure was $3.9 billion, 7.69% up from the prior year.
  • Research & Development reached $978.4 million in Q2 2025 per VRTX's latest filing, roughly flat from $979.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $998.7 million in Q4 2024 and bottomed at -$419.0 million in Q4 2021.
  • Average Research & Development over 5 years is $680.1 million, with a median of $764.2 million recorded in 2023.
  • Peak YoY movement for Research & Development: crashed 189.8% in 2021, then surged 265.65% in 2022.
  • A 5-year view of Research & Development shows it stood at -$419.0 million in 2021, then soared by 265.65% to $694.1 million in 2022, then rose by 18.8% to $824.6 million in 2023, then grew by 21.11% to $998.7 million in 2024, then fell by 2.03% to $978.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $978.4 million in Q2 2025, $979.7 million in Q1 2025, and $998.7 million in Q4 2024.